- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01208012
Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
Study Overview
Detailed Description
Type 2 Diabetes Mellitus (DM) is associated with increased cardiovascular risk and the majority of type 2 diabetic patients die due to the vascular complications of Diabetes Mellitus. In type 2 diabetic patients, an early marker in the biogenesis of atherosclerosis and cardiovascular disease is the occurrence of endothelial dysfunction with subsequent deterioration in micro- and macrovascular blood flow and tissue supply. Also several mechanistic pathways linking Diabetes Mellitus with endothelial dysfunction and cardiovascular complications are postulated. Recent studies aimed to investigate the vasoprotective effect of strict glycaemic control using conventional treatment algorithms failed to reduce cardiovascular risk in patients with Diabetes Mellitus type 2. Numerous pharmacological drugs are available to reduce blood glucose levels in type 2 diabetic patients. Beside comparable glucose lowering efficacy, some of them evolve limited or even adverse effects on vascular function and cardiovascular risk. Therefore, ideally new treatments in Diabetes Mellitus type 2 provide more than just reducing blood glucose values. Future treatments in type 2 Diabetes Mellitus will be judged on their potency to affect the cardiovascular risk profile in patients with Diabetes Mellitus type 2.
Liraglutide is a Glucagon-like peptide-1 (GLP-1) analogue shown to be effective in the treatment of type 2 Diabetes Mellitus. Liraglutide was shown to improve blood glucose levels not only by stimulating insulin secretion from the β cell, but also by improving the conversion of intact proinsulin into insulin and C-peptide in the granula of the β cell. While in rodents, GLP-1 and its analogues showed an increase in β cell regeneration and an inhibitory effect on β cell apoptosis, the effect of GLP-1 analogues on β cell mass in humans is less clear. Beyond its effects on β cells, Liraglutide and other GLP1 analogues were shown to suppress the glucagon release from α cells and to evolve a supportive effect on weight reduction by central and probably peripheral effects.
Beside these effects of GLP-1-analogues on β cell physiology and glucose metabolism, recent studies suggested several pleiotrophic effects of GLP-1 treatment which go beyond glycaemic control. Receptors for GLP-1 have been located in myocardial and endothelial cells, and GLP-1 supplementation was found to improve myocardial and endothelial function in diabetic and in non-diabetic subjects. In endothelial cells, isolated from human coronary arteries, GLP-1 rapidly activates endothelial nitric oxide synthase (eNOS) and stimulates nitric oxide (NO) production, promotes cell proliferation and inhibits glucolipoapoptosis. In addition, in transformed vascular endothelial cells, GLP-1 protects endothelial dysfunction incurred by tumor necrosis factor-α (TNF-α) through the modulation of the expression of vascular adhesion molecules and plasminogen activator inhibitor-1 (PAI-1). Chronic administration of GLP-1 analogues is associated with a significant reduction in blood pressure. Therefore it seems conceivable, that in patients with Diabetes Mellitus type 2, treatment with the GLP-1 analog Liraglutide might improve the cardiovascular risk profile beyond glucose control by stimulating endothelial NO release and by improving endothelial function.
The goal of our study is to investigate the vascular and endothelial effects of adding Liraglutide treatment to type 2 diabetic patients previously treated with Metformin.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Mainz, Germany, 55116
- IKFE Institute for Clinical Research and Development
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diabetes Mellitus type 2
- HbA1c ≥ 5.5% and ≤ 7.0%
- Treatment with Metformin (daily dose 500 - 3000 mg monotherapy, the past 3 months)
- Age 30 - 65 years
Exclusion Criteria:
- Pre-treatment with PPAR gamma agonists or DPP IV inhibitors or GLP-1 analogues within the last three months
- History of type 1 Diabetes Mellitus
- No full legal mental and physical ability to give informed consent
- Uncontrolled hypertension (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 90 mmHg)
- Anamnestic acute and chronic infections
- Inflammatory bowel disease and/or diabetic gastroparesis
- Anamnestic history of epilepsy
- Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures
- History of severe or multiple allergies
- Treatment with any other investigational drug within 3 months before trial entry
- Progressive fatal disease
- History of drug or alcohol abuse in the past 2 years
- Liver disease with ASAT or ALAT above 3 times the upper normal limit
- Serum potassium > 5.5 mmol/L
- Moderate to Severe Kidney disease with a GFR ≤ 60 ml/min
- Pregnancy or breast feeding
- Sexually active woman of childbearing potential not practicing a highly effective method of birth control as defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, sexual abstinence or vasectomised partner
- Have had more than one unexplained episode of severe hypoglycaemia (defined as requiring assistance of another person due to disabling hypoglycaemia) within 6 months prior to screening visit
- History of dehydration, diabetic precoma, diabetic ketoacidosis or diabetic gastroparesis
- Acute (within the previous 2 days) or scheduled investigation with iodine containing radiopaque material
- Acute myocardial infarction, open heart surgery or cerebral event (stroke/TIA) within the previous 6 months
- Anamnestic uncontrolled unstable angina pectoris, pericarditis, myocarditis, endocarditis, haemodynamic relevant aortic stenosis, aortic aneurysma or heart insufficiency NYHA III or IV
- Anamnestic recent pulmonary embolism or pulmonary insufficiency
- Smoking within the last 6 months (> 1 cigarette/day)
- Planned change in antidiabetic, lipid lowering or blood pressure medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Metformin
Patients taking Metformin at individual dose
|
|
Experimental: Metformin and Liraglutide
Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
|
Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells
Time Frame: timepoint 0 and after 6 and 12 weeks
|
Retinal capillary blood flow will be assessed using scanner laser doppler flowmetry.
|
timepoint 0 and after 6 and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central vascular elasticity
Time Frame: timepoint 0 and after 6 and 12 weeks
|
Central arterial elasticity will be measured by Pulse wave velocity.
|
timepoint 0 and after 6 and 12 weeks
|
Skin endothelial function and Skin oxygenation
Time Frame: timepoint 0 and after 6 and 12 weeks
|
Microvascular skin blood flow and postcapillary tissue oxygenation (sO2)will be measured.
|
timepoint 0 and after 6 and 12 weeks
|
Blood glucose control
Time Frame: timepoint 0 and after 6 and 12 weeks
|
Fasting plasma glucose will be measured.
|
timepoint 0 and after 6 and 12 weeks
|
Blood glucose control
Time Frame: up to 2 weeks before baseline and after 6 and 12 weeks after baseline
|
HbA1c will be maesured.
|
up to 2 weeks before baseline and after 6 and 12 weeks after baseline
|
Change of biomarkers of sub-clinical inflammation and cardiovascular risk
Time Frame: timepoint 0 and after 6 and 12 weeks
|
Biomarkers PAI-1, hsCRP, VCAM, E-selectin and ADMA will be measured.
|
timepoint 0 and after 6 and 12 weeks
|
Change of biomarker of heart failure
Time Frame: timepoint 0 and after 6 and 12 weeks
|
NT-pro BNP will be measured.
|
timepoint 0 and after 6 and 12 weeks
|
Insulin/ intact Proinsulin ratio, C-peptide
Time Frame: timepoint 0 and after 6 and 12 weeks
|
Insulin Intact Proinsulin and C-peptide will be maesured.
|
timepoint 0 and after 6 and 12 weeks
|
Change of body weight
Time Frame: up to 2 weeks before baseline and after 6 and 12 weeks after baseline
|
Body weight will be measured.
|
up to 2 weeks before baseline and after 6 and 12 weeks after baseline
|
Safety evaluation
Time Frame: up to 2 weeks before baseline and after 12 weeks post baseline
|
The safety evaluation includes:
|
up to 2 weeks before baseline and after 12 weeks post baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Forst, Prof. Dr., IKFE GmbH
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Lira-Vasc-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Victoza®
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Iran, Islamic Republic of
-
University of OuluTurku University Hospital; Oulu University Hospital; Tampere University Hospital and other collaboratorsCompleted
-
University of OuluTurku University Hospital; Oulu University Hospital; Tampere University HospitalEnrolling by invitation
-
University of OuluTurku University Hospital; Oulu University Hospital; Tampere University Hospital and other collaboratorsCompleted
-
SanofiCompletedDiabetes Mellitus, Type 2Brazil, United States, Finland, Spain, Austria, Canada, Czech Republic, France, Greece, Ireland, Israel, Mexico, Netherlands, Russian Federation, Slovakia, Sweden, Turkey
-
Emory UniversityNovo Nordisk A/SCompleted
-
University Hospital, Gentofte, CopenhagenNovo Nordisk A/S; University of CopenhagenCompletedMaturity-onset Diabetes of the YoungDenmark
-
The Affiliated Hospital of Qingdao UniversityCompletedTherapeutic EquivalencyChina
-
Merck Sharp & Dohme LLCTerminatedType II Diabetes Mellitus
-
Xiangya Hospital of Central South UniversityWithdrawn